BioAge Labs (BIOA) Shares Plummet After Discontinuing Trial Just 2 Months After IPO- Hagens Berman

SAN FRANCISCO, Jan. 3, 2025 /PRNewswire/ -- Shares of BioAge (NASDAQ: BIOA) have plummeted since the company's December 6 announcement of the discontinuation of a Phase 2 trial for its weight-loss drug azelaprag due to safety concerns. The abrupt halt comes just a little over two months after the company raised $198 million in a highly anticipated initial public offering in late September.Hagens Berman has opened an investigation into whether BioAge's IPO documents may have contained misstatements or omissi ...